Swiss pharma giant Roche Holding AG's RHHBY 2025 results were affected by currency headwinds. Sales totaled $74.4 billion, ...

Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ...

In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year history Excluding milestone ...

Group results In 2025, Roche achieved sales growth of 7% (2% in CHF) to CHF 61.5 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc ...

These results suggest an important takeaway: how blood sugar is controlled matters. A nutrient-dense, plant-based diet that helps maintain healthy blood sugar levels may lower your risk of diabetic ...

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, ...

Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ ®, a biosimilar to Lucentis 1 (ranibizumab), in Europe. Samsung Bioepis has been working to ...

Growth is driven by the rapidly aging global population, rising prevalence of chronic diseases such as diabetes, and ...

Under its former childhood vaccine schedule, the U.S. Centers for Disease Control and Prevention recommended that kids get 12 different vaccines protecting against 16 diseases before age 10. It didn’t ...

Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030 The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ...

About Samsung Epis Holdings Co., Ltd. As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value ...

It’s hard to think of vaccination without associating it with a sharp jab in the arm. But there are other, more gentle ways of activating the immune system, such as administering vaccines via the nose ...